Education
About Us
Working with TipRanks
Follow Us
Pfizer (PFE)
NYSE:PFE
PFE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.92 - $30.43
Previous CloseN/A
Volume12.20M
Average Volume (3M)40.94M
Market Cap
$136.74B
Enterprise Value$186.89B
Total Cash (Recent Filing)$13.25B
Total Debt (Recent Filing)$61.80B
Price to Earnings (P/E)12.8
Beta0.34
Next Earnings
Nov 04, 2025EPS Estimate
0.73Last Dividend Ex-Date
Jul 25, 2025Dividend Yield7.08%
Share Statistics
EPS (TTM)0.78
Shares Outstanding5,685,550,300
10 Day Avg. Volume46,356,376
30 Day Avg. Volume40,939,438
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.37
Enterprise Value/Revenue2.93
Enterprise Value/Gross Profit4.35
Enterprise Value/Ebitda8.21
Forecast
1Y Price Target
$28.08Price Target Upside16.27% Upside
Rating ConsensusHold
Number of Analyst Covering15
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRevenue exceeded expectations across all segments, with significant growth in key product lines.
Market ValuationPfizer shares are viewed as undervalued with potential for better fundamentals, top-line growth, and margin expansion compared to U.S. BioPharma peers.
Strategic InitiativesPfizer's overarching strategy of speed, enabled by focus, technology, and simplification, has driven recovery.
Bears Say
Acquisition ChallengesPfizer's acquisition of Global Blood Therapeutics has proven disappointing with inclacumab's failure and Oxbryta's withdrawal from the market.
Earnings OutlookEst LT EPS Growth is projected at a negative 5%.
Product DevelopmentThe termination of the Ph 3 THRIVE-131 trial for inclacumab in treating sickle cell disease is seen as a modest-negative development for Pfizer.
Pfizer News
PFE FAQ
What was Pfizer’s price range in the past 12 months?
Pfizer lowest stock price was $20.91 and its highest was $30.43 in the past 12 months.
What is Pfizer’s market cap?
Pfizer’s market cap is $136.74B.
When is Pfizer’s upcoming earnings report date?
Pfizer’s upcoming earnings report date is Nov 04, 2025 which is in 45 days.
How were Pfizer’s earnings last quarter?
Pfizer released its earnings results on Aug 06, 2025. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.2.
Is Pfizer overvalued?
According to Wall Street analysts Pfizer’s price is currently Undervalued.
Does Pfizer pay dividends?
Pfizer pays a Quarterly dividend of $0.43 which represents an annual dividend yield of 7.08%. See more information on Pfizer dividends here
What is Pfizer’s EPS estimate?
Pfizer’s EPS estimate is 0.73.
How many shares outstanding does Pfizer have?
Pfizer has 5,685,550,300 shares outstanding.
What happened to Pfizer’s price movement after its last earnings report?
Pfizer reported an EPS of $0.78 in its last earnings report, beating expectations of $0.58. Following the earnings report the stock price went down -3.313%.
Which hedge fund is a major shareholder of Pfizer?
Currently, no hedge funds are holding shares in PFE
Pfizer Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$28.08 (16.27% Upside)
$28.08 (16.27% Upside)
Blogger Sentiment
Bullish
PFE Sentiment 90%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 545.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.12%
12-Months-Change
Fundamentals
Return on Equity
12.16%
Trailing 12-Months
Asset Growth
-4.67%
Trailing 12-Months
Company Description
Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
PFE Company Deck
PFE Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment overall, with Pfizer showing strong financial performance, significant advancements in its R&D pipeline, and effective cost management. However, there are some challenges, particularly related to pricing pressures from the IRA Medicare Part D redesign and competitive pressures in the oncology sector.View all PFE earnings summariesPFE Revenue Breakdown
47.36% Primary Care
26.17% Specialty Care
24.54% Oncology
1.80% PFIZER CENTREONE
0.13% PFIZER IGNITE
PFE Stock 12 Month Forecast
Average Price Target
$28.08
▲(16.27% Upside)
Technical Analysis
Ownership Overview
0.03% Insiders
16.45% Mutual Funds
11.65% Other Institutional Investors
50.50% Public Companies and Individual Investors